{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:36:46Z","timestamp":1788791806501,"version":"build-2803163510"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T00:00:00Z","timestamp":1346716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s11894-012-0284-2","type":"journal-article","created":{"date-parts":[[2012,9,3]],"date-time":"2012-09-03T04:24:11Z","timestamp":1346646251000},"page":"439-445","source":"Crossref","is-referenced-by-count":36,"title":["Antibiotics for Irritable Bowel Syndrome: Rationale and Current Evidence"],"prefix":"10.1007","volume":"14","author":[{"given":"Amit H.","family":"Sachdev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,4]]},"reference":[{"issue":"3","key":"284_CR1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0016-5085(82)80186-8","volume":"83","author":"DA Drossman","year":"1982","unstructured":"Drossman DA, Sandler RS, McKee DC, et al. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology. 1982;83(3):529\u201334.","journal-title":"Gastroenterology"},{"issue":"2","key":"284_CR2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0016-5085(80)90142-0","volume":"79","author":"WG Thompson","year":"1980","unstructured":"Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology. 1980;79(2):283\u20138.","journal-title":"Gastroenterology"},{"key":"284_CR3","first-page":"117","volume-title":"The functional gastrointestinal disorders","author":"WG Thompson","year":"1994","unstructured":"Thompson WG. The functional gastrointestinal bowel disorders. In: Drossman DA, editor. The functional gastrointestinal disorders. Boston: Little, Brown; 1994. p. 117\u201334."},{"issue":"5A","key":"284_CR4","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.1016\/S0002-9343(99)00078-9","volume":"107","author":"WE Whitehead","year":"1999","unstructured":"Whitehead WE. Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination. Am J Med. 1999;107(5A):33S\u201340S.","journal-title":"Am J Med"},{"issue":"Suppl 2","key":"284_CR5","doi-asserted-by":"crossref","first-page":"II43","DOI":"10.1136\/gut.45.2008.ii43","volume":"45","author":"WG Thompson","year":"1999","unstructured":"Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45 Suppl 2:II43\u20137.","journal-title":"Gut"},{"issue":"1","key":"284_CR6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10620-008-0694-z","volume":"55","author":"M Pimentel","year":"2010","unstructured":"Pimentel M, Hwang L, Melmed GY, et al. New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA\/IBS diagnostic strategy. Dig Dis Sci. 2010;55(1):145\u20139.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"284_CR7","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","volume":"130","author":"GF Longstreth","year":"2006","unstructured":"Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480\u201391.","journal-title":"Gastroenterology"},{"issue":"3","key":"284_CR8","first-page":"237","volume":"15","author":"DA Drossman","year":"2006","unstructured":"Drossman DA, Dumitrascu DL. Rome III: new standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15(3):237\u201341.","journal-title":"J Gastrointestin Liver Dis"},{"key":"284_CR9","unstructured":"Guidelines--Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15(3):307\u201312"},{"issue":"1","key":"284_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0016-5085(84)90119-7","volume":"87","author":"W Kruis","year":"1984","unstructured":"Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology. 1984;87(1):1\u20137.","journal-title":"Gastroenterology"},{"issue":"22","key":"284_CR11","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1056\/NEJMra035579","volume":"349","author":"HR Mertz","year":"2003","unstructured":"Mertz HR. Irritable bowel syndrome. N Engl J Med. 2003;349(22):2136\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"284_CR12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cgh.2008.07.008","volume":"7","author":"Y Ringel","year":"2009","unstructured":"Ringel Y, Williams RE, Kalilani L, et al. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7(1):68\u201372. quiz 3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"284_CR13","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/BF01296098","volume":"38","author":"DP McKee","year":"1993","unstructured":"McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder. Dig Dis Sci. 1993;38(10):1773\u201382.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"284_CR14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/BF01296097","volume":"38","author":"DP McKee","year":"1993","unstructured":"McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility. Dig Dis Sci. 1993;38(10):1761\u201372.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"284_CR15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00000658-199808000-00007","volume":"228","author":"VB Nieuwenhuijs","year":"1998","unstructured":"Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, et al. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg. 1998;228(2):188\u201393.","journal-title":"Ann Surg"},{"issue":"12","key":"284_CR16","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1023\/A:1021039032413","volume":"47","author":"M Pimentel","year":"2002","unstructured":"Pimentel M, Soffer EE, Chow EJ, et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47(12):2639\u201343.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"284_CR17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(00)70170-3","volume":"118","author":"H Mertz","year":"2000","unstructured":"Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology. 2000;118(5):842\u20138.","journal-title":"Gastroenterology"},{"issue":"1","key":"284_CR18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1540\/jsmr.45.15","volume":"45","author":"N Manabe","year":"2009","unstructured":"Manabe N, Tanaka T, Hata J, et al. Pathophysiology underlying irritable bowel syndrome\u2013from the viewpoint of dysfunction of autonomic nervous system activity. J Smooth Muscle Res. 2009;45(1):15\u201323.","journal-title":"J Smooth Muscle Res"},{"issue":"6","key":"284_CR19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/gut.33.6.825","volume":"33","author":"WE Whitehead","year":"1992","unstructured":"Whitehead WE, Crowell MD, Robinson JC, et al. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut. 1992;33(6):825\u201330.","journal-title":"Gut"},{"issue":"2","key":"284_CR20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1025582728271","volume":"20","author":"RL Levy","year":"1997","unstructured":"Levy RL, Cain KC, Jarrett M, et al. The relationship between daily life stress and gastrointestinal symptoms in women with irritable bowel syndrome. J Behav Med. 1997;20(2):177\u201393.","journal-title":"J Behav Med"},{"issue":"2","key":"284_CR21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jpsychores.2007.10.010","volume":"64","author":"EB Blanchard","year":"2008","unstructured":"Blanchard EB, Lackner JM, Jaccard J, et al. The role of stress in symptom exacerbation among IBS patients. J Psychosom Res. 2008;64(2):119\u201328.","journal-title":"J Psychosom Res"},{"issue":"10","key":"284_CR22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/MCG.0b013e3181ef3476","volume":"44","author":"D Yamini","year":"2010","unstructured":"Yamini D, Pimentel M. Irritable bowel syndrome and small intestinal bacterial overgrowth. J Clin Gastroenterol. 2010;44(10):672\u20135.","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"284_CR23","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/gut.2006.108712","volume":"56","author":"I Posserud","year":"2007","unstructured":"\u2022 Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802\u20138. Provided the first conclusive direct evidence for SIBO in IBS i.e. evidence based on culture of the small bowel rather than breath testing.","journal-title":"Gut"},{"key":"284_CR24","doi-asserted-by":"crossref","unstructured":"Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with Irritable Bowel Syndrome. Dig Dis Sci. 2012","DOI":"10.1007\/s10620-012-2033-7"},{"issue":"12","key":"284_CR25","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.cgh.2009.06.031","volume":"7","author":"AC Ford","year":"2009","unstructured":"Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279\u201386.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"284_CR26","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s10620-010-1276-4","volume":"55","author":"ED Shah","year":"2010","unstructured":"Shah ED, Basseri RJ, Chong K, et al. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55(9):2441\u20139.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"284_CR27","first-page":"109","volume":"15","author":"EM Quigley","year":"2006","unstructured":"Quigley EM. New perspectives on the role of the intestinal flora in health and disease. J Gastrointestin Liver Dis. 2006;15(2):109\u201310.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"5778","key":"284_CR28","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.1124234","volume":"312","author":"SR Gill","year":"2006","unstructured":"Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312(5778):1355\u20139.","journal-title":"Science"},{"issue":"7164","key":"284_CR29","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nature06244","volume":"449","author":"PJ Turnbaugh","year":"2007","unstructured":"Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007;449(7164):804\u201310.","journal-title":"Nature"},{"issue":"12","key":"284_CR30","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","volume":"95","author":"M Pimentel","year":"2000","unstructured":"Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"284_CR31","first-page":"412","volume":"98","author":"M Pimentel","year":"2003","unstructured":"Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"11\u201312","key":"284_CR32","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1365-2036.2005.02690.x","volume":"22","author":"A Lupascu","year":"2005","unstructured":"Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(11\u201312):1157\u201360.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"284_CR33","first-page":"89","volume":"52","author":"L Cuoco","year":"2006","unstructured":"Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52(1):89\u201395.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"284_CR34","first-page":"139","volume":"52","author":"M Majewski","year":"2007","unstructured":"\u2022 Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139\u201342. Important early study demonstrating SIBO in IBS pa#ents and the efficacy of antibiotic (rifaximin) treatment in allevia#ng symptoms.","journal-title":"Adv Med Sci"},{"issue":"2","key":"284_CR35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","volume":"101","author":"AI Sharara","year":"2006","unstructured":"Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326\u201333.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"284_CR36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","volume":"364","author":"M Pimentel","year":"2011","unstructured":"\u2022 Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22\u201332. Describes two large phase 3, double\u2010blind, placebo\u2010controlled trials (TARGET 1 and TARGET 2) which showed that treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms in patients who had IBS without constipation.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"284_CR37","first-page":"S3","volume":"5","author":"HC Lin","year":"2005","unstructured":"Lin HC, Pimentel M. Bacterial concepts in irritable bowel syndrome. Rev Gastroenterol Disord. 2005;5 Suppl 3:S3\u20139.","journal-title":"Rev Gastroenterol Disord"},{"issue":"7","key":"284_CR38","first-page":"455","volume":"7","author":"RJ Basseri","year":"2011","unstructured":"Basseri RJ, Weitsman S, Barlow GM, et al. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (NY). 2011;7(7):455\u201393.","journal-title":"Gastroenterol Hepatol (NY)"},{"issue":"11","key":"284_CR39","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/0966-842X(96)10057-3","volume":"4","author":"RD Berg","year":"1996","unstructured":"Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol. 1996;4(11):430\u20135.","journal-title":"Trends Microbiol"},{"key":"284_CR40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0065-2164(04)54010-8","volume":"54","author":"S Macfarlane","year":"2004","unstructured":"Macfarlane S, Macfarlane GT. Bacterial diversity in the human gut. Adv Appl Microbiol. 2004;54:261\u201389.","journal-title":"Adv Appl Microbiol"},{"issue":"5717","key":"284_CR41","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1126\/science.1104816","volume":"307","author":"F Backhed","year":"2005","unstructured":"Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307(5717):1915\u201320.","journal-title":"Science"},{"issue":"7","key":"284_CR42","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/sj.embor.7400731","volume":"7","author":"AM O\u2019Hara","year":"2006","unstructured":"O\u2019Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688\u201393.","journal-title":"EMBO Rep"},{"issue":"34","key":"284_CR43","doi-asserted-by":"crossref","first-page":"13780","DOI":"10.1073\/pnas.0706625104","volume":"104","author":"DN Frank","year":"2007","unstructured":"Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104(34):13780\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"284_CR44","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3748\/wjg.v11.i8.1131","volume":"11","author":"A Swidsinski","year":"2005","unstructured":"Swidsinski A, Loening-Baucke V, Lochs H, et al. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol. 2005;11(8):1131\u201340.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"284_CR45","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0016-5085(19)34122-8","volume":"53","author":"SL Gorbach","year":"1967","unstructured":"Gorbach SL, Plaut AG, Nahas L, et al. Studies of intestinal microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora. Gastroenterology. 1967;53(6):856\u201367.","journal-title":"Gastroenterology"},{"key":"284_CR46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev.mi.31.100177.000543","volume":"31","author":"DC Savage","year":"1977","unstructured":"Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107\u201333.","journal-title":"Annu Rev Microbiol"},{"issue":"5","key":"284_CR47","doi-asserted-by":"crossref","first-page":"1035S","DOI":"10.1093\/ajcn\/69.5.1035s","volume":"69","author":"RI Mackie","year":"1999","unstructured":"Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr. 1999;69(5):1035S\u201345S.","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"284_CR48","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1371\/journal.pbio.0050177","volume":"5","author":"C Palmer","year":"2007","unstructured":"Palmer C, Bik EM, DiGiulio DB, et al. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5(7):e177.","journal-title":"PLoS Biol"},{"issue":"1","key":"284_CR49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.gtc.2010.12.010","volume":"40","author":"M Pimentel","year":"2011","unstructured":"Pimentel M, Chang C. Inflammation and microflora. Gastroenterol Clin North Am. 2011;40(1):69\u201385.","journal-title":"Gastroenterol Clin North Am"},{"issue":"3","key":"284_CR50","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1152\/physrev.00045.2009","volume":"90","author":"I Sekirov","year":"2010","unstructured":"Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859\u2013904.","journal-title":"Physiol Rev"},{"issue":"2","key":"284_CR51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pharmthera.2011.01.012","volume":"130","author":"PD Cani","year":"2011","unstructured":"Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther. 2011;130(2):202\u201312.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"284_CR52","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrgastro.2010.172","volume":"7","author":"A Abu-Shanab","year":"2010","unstructured":"Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(12):691\u2013701.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"284_CR53","doi-asserted-by":"crossref","unstructured":"Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res Pract. 2010;2010.","DOI":"10.1155\/2010\/212563"},{"key":"284_CR54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev-med-012510-175505","volume":"62","author":"G Musso","year":"2011","unstructured":"Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med. 2011;62:361\u201380.","journal-title":"Annu Rev Med"},{"issue":"Suppl 2","key":"284_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2004.02036.x","volume":"20","author":"G Barbara","year":"2004","unstructured":"Barbara G, De Giorgio R, Stanghellini V, et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20 Suppl 2:1\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"284_CR56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2006.11.039","volume":"132","author":"G Barbara","year":"2007","unstructured":"Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132(1):26\u201337.","journal-title":"Gastroenterology"},{"issue":"2","key":"284_CR57","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ajcn\/39.2.338","volume":"39","author":"NI McNeil","year":"1984","unstructured":"McNeil NI. The contribution of the large intestine to energy supplies in man. Am J Clin Nutr. 1984;39(2):338\u201342.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"284_CR58","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ajg.2009.678","volume":"105","author":"M Pimentel","year":"2010","unstructured":"Pimentel M. Evaluating a bacterial hypothesis in IBS using a modification of Koch\u2019s postulates: part 1. Am J Gastroenterol. 2010;105(4):718\u201321.","journal-title":"Am J Gastroenterol"},{"key":"284_CR59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.12938\/bifidus1982.1.1_3","volume":"1","author":"T Mitsuoka","year":"1982","unstructured":"Mitsuoka T. Recent trends in research on intestinal flora. Bifido Microflora. 1982;1:3\u201324.","journal-title":"Bifido Microflora"},{"key":"284_CR60","first-page":"387","volume":"38","author":"PP Toskes","year":"1993","unstructured":"Toskes PP. Bacterial overgrowth of the gastrointestinal tract. Adv Intern Med. 1993;38:387\u2013407.","journal-title":"Adv Intern Med"},{"issue":"1","key":"284_CR61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.giec.2008.12.004","volume":"19","author":"Y Ringel","year":"2009","unstructured":"Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am. 2009;19(1):141\u201350. vii.","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"1","key":"284_CR62","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.gastro.2007.04.005","volume":"133","author":"A Kassinen","year":"2007","unstructured":"Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133(1):24\u201333.","journal-title":"Gastroenterology"},{"issue":"1","key":"284_CR63","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0016-5085(84)90606-1","volume":"86","author":"GL Simon","year":"1984","unstructured":"Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology. 1984;86(1):174\u201393.","journal-title":"Gastroenterology"},{"issue":"7122","key":"284_CR64","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/4441022a","volume":"444","author":"RE Ley","year":"2006","unstructured":"Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022\u20133.","journal-title":"Nature"},{"issue":"4","key":"284_CR65","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11938-007-0076-1","volume":"10","author":"M Pimentel","year":"2007","unstructured":"Pimentel M, Lezcano S. Irritable bowel syndrome: bacterial overgrowth\u2013what\u2019s known and what to do. Curr Treat Options Gastroenterol. 2007;10(4):328\u201337.","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"9","key":"284_CR66","first-page":"1334","volume":"57","author":"M Pimentel","year":"2008","unstructured":"Pimentel M. The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: IBS vs healthy controls (not historical definitions). Gut. 2008;57(9):1334\u20135. author reply 5.","journal-title":"Gut"},{"issue":"5 Pt 1","key":"284_CR67","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0016-5085(79)91337-4","volume":"76","author":"CE King","year":"1979","unstructured":"King CE, Toskes PP. Small intestine bacterial overgrowth. Gastroenterology. 1979;76(5 Pt 1):1035\u201355.","journal-title":"Gastroenterology"},{"issue":"6","key":"284_CR68","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1172\/JCI108740","volume":"59","author":"G Vantrappen","year":"1977","unstructured":"Vantrappen G, Janssens J, Hellemans J, et al. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59(6):1158\u201366.","journal-title":"J Clin Invest"},{"issue":"29","key":"284_CR69","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.3748\/wjg.v16.i29.3680","volume":"16","author":"SR Jee","year":"2010","unstructured":"Jee SR, Morales W, Low K, et al. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol. 2010;16(29):3680\u20136.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"284_CR70","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10620-007-0065-1","volume":"53","author":"R Khoshini","year":"2008","unstructured":"Khoshini R, Dai SC, Lezcano S, et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53(6):1443\u201354.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"284_CR71","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s10620-009-1012-0","volume":"55","author":"AB Sahakian","year":"2010","unstructured":"Sahakian AB, Jee SR, Pimentel M. Methane and the gastrointestinal tract. Dig Dis Sci. 2010;55(8):2135\u201343.","journal-title":"Dig Dis Sci"},{"key":"284_CR72","doi-asserted-by":"crossref","first-page":"S629","DOI":"10.1016\/S0016-5085(10)62898-3","volume":"138","author":"D Kunkel","year":"2010","unstructured":"Kunkel D, Makhani MD, Chong K, et al. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Gastroenterology. 2010;138:S629.","journal-title":"Gastroenterology"},{"issue":"3","key":"284_CR73","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/gut.2005.075127","volume":"55","author":"M Simren","year":"2006","unstructured":"Simren M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut. 2006;55(3):297\u2013303.","journal-title":"Gut"},{"issue":"4","key":"284_CR74","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1572-0241.2008.01785.x","volume":"103","author":"JR Bratten","year":"2008","unstructured":"Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol. 2008;103(4):958\u201363.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"284_CR75","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/0016-5085(90)90818-L","volume":"98","author":"GR Corazza","year":"1990","unstructured":"Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990;98(2):302\u20139.","journal-title":"Gastroenterology"},{"issue":"7","key":"284_CR76","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s10620-011-1569-2","volume":"56","author":"YH Youn","year":"2011","unstructured":"Youn YH, Park JS, Jahng JH, et al. Relationships among the lactulose breath test, intestinal gas volume, and gastrointestinal symptoms in patients with irritable bowel syndrome. Dig Dis Sci. 2011;56(7):2059\u201366.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"284_CR77","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1111\/j.1572-0241.2001.04668.x","volume":"96","author":"TM Bauer","year":"2001","unstructured":"Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"284_CR78","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s10620-007-9977-z","volume":"53","author":"M Pimentel","year":"2008","unstructured":"Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci. 2008;53(4):982\u20139.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"284_CR79","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2036.2006.02938.x","volume":"24","author":"J Tack","year":"2006","unstructured":"Tack J, Fried M, Houghton LA, et al. Systematic review: the efficacy of treatments for irritable bowel syndrome-a European perspective. Aliment Pharmacol Ther. 2006;24(2):183\u2013205.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"284_CR80","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/gut.42.1.42","volume":"42","author":"CP Bearcroft","year":"1998","unstructured":"Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut. 1998;42(1):42\u20136.","journal-title":"Gut"},{"issue":"14","key":"284_CR81","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","volume":"161","author":"M Camilleri","year":"2001","unstructured":"Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161(14):1733\u201340.","journal-title":"Arch Intern Med"},{"issue":"6","key":"284_CR82","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11894-003-0035-5","volume":"5","author":"BD Cash","year":"2003","unstructured":"Cash BD, Chey WD. Advances in the management of irritable bowel syndrome. Curr Gastroenterol Rep. 2003;5(6):468\u201375.","journal-title":"Curr Gastroenterol Rep"},{"issue":"10","key":"284_CR83","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","volume":"15","author":"SA Muller-Lissner","year":"2001","unstructured":"Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15(10):1655\u201366.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"284_CR84","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","volume":"16","author":"J Novick","year":"2002","unstructured":"Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002;16(11):1877\u201388.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"284_CR85","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0016-5085(03)00669-3","volume":"125","author":"DA Drossman","year":"2003","unstructured":"Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125(1):19\u201331.","journal-title":"Gastroenterology"},{"issue":"1","key":"284_CR86","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.2000.00684.x","volume":"14","author":"KD Bardhan","year":"2000","unstructured":"Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2000;14(1):23\u201334.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"284_CR87","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","volume":"145","author":"M Pimentel","year":"2006","unstructured":"Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145(8):557\u201363.","journal-title":"Ann Intern Med"},{"issue":"4, Supplement 1","key":"284_CR88","doi-asserted-by":"crossref","first-page":"A-545","DOI":"10.1016\/S0016-5085(08)62544-5","volume":"134","author":"A Lembo","year":"2008","unstructured":"Lembo A, Zakko SF, Ferreira NL, et al. T1390 Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology. 2008;134(4, Supplement 1):A-545.","journal-title":"Gastroenterology"},{"issue":"4","key":"284_CR89","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11894-005-0025-x","volume":"7","author":"GW Citters Van","year":"2005","unstructured":"Van Citters GW, Lin HC. Management of small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2005;7(4):317\u201320.","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"284_CR90","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10620-007-9839-8","volume":"53","author":"J Yang","year":"2008","unstructured":"Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53(1):169\u201374.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"284_CR91","first-page":"365","volume":"3","author":"A Lamanna","year":"1984","unstructured":"Lamanna A, Orsi A. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia. 1984;3(6):365\u20137.","journal-title":"Chemioterapia"},{"issue":"2","key":"284_CR92","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/14787210.3.2.201","volume":"3","author":"L Gerard","year":"2005","unstructured":"Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther. 2005;3(2):201\u201311.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 1","key":"284_CR93","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","volume":"51","author":"ZD Jiang","year":"2005","unstructured":"Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity\u2013a review. Chemotherapy. 2005;51 Suppl 1:67\u201372.","journal-title":"Chemotherapy"},{"issue":"2","key":"284_CR94","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0732-8893(93)90004-Q","volume":"16","author":"WW Hoover","year":"1993","unstructured":"Hoover WW, Gerlach EH, Hoban DJ, et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis. 1993;16(2):111\u20138.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"284_CR95","first-page":"483","volume":"13","author":"S Ripa","year":"1987","unstructured":"Ripa S, Mignini F, Prenna M, et al. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. Drugs Exp Clin Res. 1987;13(8):483\u20138.","journal-title":"Drugs Exp Clin Res"},{"issue":"6","key":"284_CR96","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/jac\/47.6.904","volume":"47","author":"JM Sierra","year":"2001","unstructured":"Sierra JM, Navia MM, Vargas M, et al. In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. J Antimicrob Chemother. 2001;47(6):904\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"284_CR97","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2036.2000.00751.x","volume":"14","author":"M Stefano Di","year":"2000","unstructured":"Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14(5):551\u20136.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"284_CR98","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2036.2005.02516.x","volume":"22","author":"EC Lauritano","year":"2005","unstructured":"Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22(1):31\u20135.","journal-title":"Aliment Pharmacol Ther"},{"key":"284_CR99","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","volume":"145","author":"M Pimentel","year":"2006","unstructured":"Pimentel M, Park S, Kane SV, et al. Rifaximin, a non-absorbable antibiotic improves the symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled study. Ann Intern Med. 2006;145:557\u201363.","journal-title":"Ann Intern Med"},{"issue":"7","key":"284_CR100","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s10620-011-1728-5","volume":"56","author":"M Pimentel","year":"2011","unstructured":"\u2022 Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci. 2011;56(7):2067\u201372. Demonstrated that for subjects with nonconstipated IBS, retreatment with rifaximin was successful up to five times with no significant reduction in benefit, or of duration of benefit, for successive retreatments.","journal-title":"Dig Dis Sci"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-012-0284-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-012-0284-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-012-0284-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T03:51:14Z","timestamp":1594612274000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-012-0284-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,4]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1007\/s11894-012-0284-2","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,4]]}}}